Glutathione (GSH)

Glutathione is one of the strangest entries in this catalog because it is simultaneously the most familiar molecule and the least well-characterised administered therapeutic. Every cell in your body already contains glutathione at millimolar concentrations. It is the primary intracellular thiol antioxidant. Its biology is textbook: the cysteine thiol (-SH) reduces reactive oxygen species; the molecule conjugates with toxins and xenobiotics via glutathione S-transferase for hepatic Phase II detoxification export; it recycles oxidised vitamin C and vitamin E back to active forms; it supports T-cell proliferation and NK-cell cytotoxicity; and — the mechanism behind its cosmetic use — it inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis. Alton Meister's foundational 1988 review remains the reference document for the endogenous biology.

Chemically, glutathione is a tripeptide (γ-L-glutamyl-L-cysteinyl-glycine) but with a design detail that matters: the bond between glutamate and cysteine uses the γ-carboxyl of glutamate rather than the standard α-carboxyl. That non-standard bond protects the molecule from routine peptidase degradation and is why the intracellular glutathione pool can be so large and stable. It also has consequences for oral bioavailability: standard digestive peptidases handle the cysteine-glycine bond fine but struggle less with the γ-glutamyl bond, and most orally administered whole glutathione is broken down in the gut into its constituent amino acids before absorption. Witschi et al. 1992 and Richie et al. 2015 are the reference bioavailability studies. Liposomal and sublingual formulations claim to improve absorption, with mixed evidence support.

The clinical evidence picture divides sharply by administration route. Oral: weak bioavailability of whole molecule, some evidence that liposomal or sublingual formulations raise intracellular glutathione levels, mixed clinical outcomes across various conditions. Injectable IV or subcutaneous: no FDA-approved therapeutic, small clinical trials in Parkinson disease (Sechi et al. 1996) with mixed follow-up, and — most importantly — a substantial off-label cosmetic skin-lightening industry, particularly in Southeast Asia. The Philippines FDA issued a public warning in 2011 about serious adverse events (Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic and renal dysfunction, thyroid dysfunction) reported with injectable glutathione for cosmetic use.

The skin-lightening mechanism is real: glutathione inhibits tyrosinase, which catalyses the rate-limiting step of melanin synthesis, shifting melanin production away from the darker eumelanin toward the lighter pheomelanin. At sustained high doses this can produce visible skin lightening. The mechanism is real; the safety framework for the doses required to produce cosmetic effect is not equivalent to an approved therapeutic use. Consumers pursuing cosmetic glutathione use should be aware that the cosmetic effect takes 4–12 weeks minimum at sustained dosing to become visible, and that the sustained high-dose regimens carry the specific safety signals that the Philippines FDA flagged.

Glutathione is one of the strangest entries in this catalog because it is simultaneously the most familiar molecule and the least well-characterised administered therapeutic. Every cell in your body already contains glutathione at millimolar concentrations. It is the primary intracellular thiol antioxidant. Its biology is textbook: the cysteine thiol (-SH) reduces reactive oxygen species; the molecule conjugates with toxins and xenobiotics via glutathione S-transferase for hepatic Phase II detoxification export; it recycles oxidised vitamin C and vitamin E back to active forms; it supports T-cell proliferation and NK-cell cytotoxicity; and — the mechanism behind its cosmetic use — it inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis. Alton Meister's foundational 1988 review remains the reference document for the endogenous biology.

Chemically, glutathione is a tripeptide (γ-L-glutamyl-L-cysteinyl-glycine) but with a design detail that matters: the bond between glutamate and cysteine uses the γ-carboxyl of glutamate rather than the standard α-carboxyl. That non-standard bond protects the molecule from routine peptidase degradation and is why the intracellular glutathione pool can be so large and stable. It also has consequences for oral bioavailability: standard digestive peptidases handle the cysteine-glycine bond fine but struggle less with the γ-glutamyl bond, and most orally administered whole glutathione is broken down in the gut into its constituent amino acids before absorption. Witschi et al. 1992 and Richie et al. 2015 are the reference bioavailability studies. Liposomal and sublingual formulations claim to improve absorption, with mixed evidence support.

The clinical evidence picture divides sharply by administration route. Oral: weak bioavailability of whole molecule, some evidence that liposomal or sublingual formulations raise intracellular glutathione levels, mixed clinical outcomes across various conditions. Injectable IV or subcutaneous: no FDA-approved therapeutic, small clinical trials in Parkinson disease (Sechi et al. 1996) with mixed follow-up, and — most importantly — a substantial off-label cosmetic skin-lightening industry, particularly in Southeast Asia. The Philippines FDA issued a public warning in 2011 about serious adverse events (Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic and renal dysfunction, thyroid dysfunction) reported with injectable glutathione for cosmetic use.

The skin-lightening mechanism is real: glutathione inhibits tyrosinase, which catalyses the rate-limiting step of melanin synthesis, shifting melanin production away from the darker eumelanin toward the lighter pheomelanin. At sustained high doses this can produce visible skin lightening. The mechanism is real; the safety framework for the doses required to produce cosmetic effect is not equivalent to an approved therapeutic use. Consumers pursuing cosmetic glutathione use should be aware that the cosmetic effect takes 4–12 weeks minimum at sustained dosing to become visible, and that the sustained high-dose regimens carry the specific safety signals that the Philippines FDA flagged.

Alton Meister's 1988 review remains the reference document for the endogenous biology of glutathione — its synthesis, redox cycling, conjugation with xenobiotics, and role in cellular protection. That endogenous biology is one of the best-characterised in cell biology.

Sechi et al. 1996 reported the pilot IV glutathione trial in Parkinson disease that has been foundational to the neurology-related use of the compound. Follow-up trials have produced mixed results.

Witschi et al. 1992 and Richie et al. 2015 are the reference bioavailability studies for oral glutathione, both showing that whole-molecule absorption is poor and that oral supplementation must overcome significant first-pass loss.

The Philippines FDA public warning of 2011 is the primary regulator document about the cosmetic-use safety signals. It documents Stevens-Johnson syndrome, toxic epidermal necrolysis, and hepatic and renal dysfunction reports in the context of injectable cosmetic glutathione use in Southeast Asia. Any consumer considering this use should read that warning directly.

Injectable glutathione has no FDA-approved therapeutic indication. Oral, liposomal, and sublingual glutathione are widely sold as dietary supplements. The Philippines FDA issued a public warning in 2011 about serious adverse events from injectable glutathione for cosmetic skin lightening, and similar warnings have followed from other regulators in the region.

The compound's endogenous biology is textbook-well-established. Its therapeutic use as an administered drug is much less well-established — clinical trials in Parkinson disease (Sechi et al. 1996) and non-alcoholic fatty liver disease have produced mixed results at small scale, and no FDA-approved indication exists.